A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in patients with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane
Journal of Clinical Oncology Feb 29, 2020
Vaishampayan UN, De Wit EJ, Shore ND, et al. - In order to determine the objective response rate (ORR), and additionally PSA response, PSA-PFS, time to skeletal related events and progression, duration of response, disease control rate and safety of ModraDoc006/r [oral combination of ModraDoc006 (oral tablet formulation of docetaxel) and ritonavir (/r; an inhibitor of cytochrome p450 3A4 and P-glycoprotein)] bi-daily QW vs docetaxel IV 75 mg/m2 Q3W in mCRPC pts with measurable disease per RECIST 1.1, suitable for docetaxel therapy, researchers have planned an open label 1:1 randomized phase 2b trial, given a phase Ib trial in mCRPC pts has already established safety and preliminary efficacy of ModraDoc006/r. No previous therapy with taxanes is allowed. The eligible patients are given thirty (30) mg ModraDoc006 combined with 200 mg /r in morning and 20 mg ModraDoc006 with 100 mg /r in evening on days 1, 8 and 15 of a 21 day cycle. 5 mg oral prednisone twice daily will be given to all patients. Therapy is continued until progression, unacceptable toxicity or patient desire. They will record patient-reported outcomes and health-related quality of life with treatment satisfaction and FACT-P questionnaires. Experts anticipated that the effectiveness of ModraDoc006/r will be at least equal to that of docetaxel IV. A sample size of 50 evaluable pts per arm will assess an estimated ORR of 25% in each arm, with a 5% two-sided alpha and power of 83.7%. Overall, it has been concluded that ModraDoc006/r provides convenience of oral administration, has reduced myelosuppressive toxicity and potential improved efficacy over IV docetaxel, and with all these qualities, it signifies progress in prostate cancer therapeutics.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins